ClinicalTrials.gg
RecruitingNCT06507202Updated Jul 18, 2024

Comparison of Remimazolam and Propofol for Recovery of Ambulatory Upper Airway Surgery

A Phase 4 interventional study of Remimazolam and Propofol in Laryngeal Disease, Pharyngeal Diseases and Oral Cavity Disease, sponsored by Chung-Ang University Gwangmyeong Hospital. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-07-18.

Sponsored by Chung-Ang University Gwangmyeong Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare the effects of remimazolam and propofol on postoperative recovery time, complications, and safety in patients undergoing ambulatory upper airway surgery under general anesthesia.

Read the detailed description

Patients scheduled for ambulatory upper airway (including nasal cavity, oral cavity, pharynx, larynx) surgery and who agree to participate in the study will be randomly assigned to the Remimazolam group and the Propofol group. In the Remimazolam group, general anesthesia is induced and maintained by continuous infusion of remimazolam and remifentanil. Once the surgery is completed, general anesthesia is recovered with flumazenil. In the Propofol group, general anesthesia is induced and maintained by continuous infusion of propofol and remifentanil using a target concentration controlled infusion method. In both groups, rocuronium is used for neuromuscular blokade, and sugammadex is used for reversal of neuromuscular blockade.

When the surgery is completed, recovery time, occurrence of adverse events, and anesthesia recovery indicators are examined in 3 stages: in the operating room, while staying in the post-anesthesia care unit(PACU), and while staying in the day surgery center.

02

Conditions studied

  • Laryngeal Disease
  • Pharyngeal Diseases
  • Oral Cavity Disease
  • Nasal Disease

Keywords

  • remimazolam
  • upper airway surgery
  • ambulatory surgery
03

In context

Laryngeal Diseases

147 studies on the registry are indexed under Laryngeal Diseases; 26 are open to participants now.

This study's planned enrollment of 116 is above the median of 50 across 109 interventional studies indexed under Laryngeal Diseases.

Browse Laryngeal Diseases studies →

Lead sponsor

Chung-Ang University Gwangmyeong Hospital is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (age 19 or older) undergoing ambulatory upper respiratory tract (nasal cavity, oral cavity, pharynx, larynx) surgery under general anesthesia
  • physical class classification I, II, and III

Exclusion criteria

Exclusion Criteria:

  • Patients who refused to participate in the study
  • Pregnant patients
  • Patients with a history of to drugs or additives used during surgery
  • Patients with acute narrow-angle glaucoma
  • Alcohol or drug dependent patients
  • Patients with class C liver dysfunction
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Remimazolam group

    General anesthesia is induced by continuously injecting remimazolam (6 mg/kg/h) and remifentanil (2-6 ng/ml, target concentration controlled infusion) through an infusion pump. Afterwards, when the patient loses consciousness, rocuronium 0.6 mg/kg is injected for endotracheal intubation, and anesthesia is maintained with remimazolam (1-2 mg/kg/hr) and remifentanil after endotracheal intubation. When the surgery is completed, all anesthetic drugs being administered are stopped, and general anesthesia is terminated with flumazenil and sugammadex.

    Drug: Remimazolam

  • Active comparator
    Propofol group

    General anesthesia is induced by continuously injecting propofol (2-6 mg/ml, target concentration controlled injection) and remifentanil (2-6 ng/ml, target concentration controlled injection) using a TCI infusion pump. Afterwards, when the patient loses consciousness, rocuronium 0.6mg/kg is injected for endotracheal intubation, and anesthesia is maintained with propofol and remifentanil after endotracheal intubation. When the surgery is completed, all anesthetic drugs being administered are stopped, and general anesthesia is terminated through sugammadex.

    Drug: Propofol

Interventions

  • General anesthesia is induced and maintained by continuous infusion of remimazolam and remifentanil, and recovered with flumazenil.

    Also known as: Byfavo

  • General anesthesia is induced and maintained by continuous infusion of propofol and remifentanil.

    Also known as: Fresofol

06

What researchers measure

Primary outcomes

  1. Fit-for-discharge time

    Evaluated on a scale of 0 to 10 through the Modified Post Anesthetic Discharge Scoring System (MPADSS); a score of 9 or higher meets the discharge criteria.

    Time frame: 15 minutes after surgery

Secondary outcomes

  1. Time to eye opening, time to extubate, time to postanesthetic care unit (PACU) transfer

    Measured at operating room, using a timer from the end of surgery

    Time frame: 1 minute

  2. postanesthetic care unit (PCAU) stay time, Day surgery center stay time

    Measured from entering to exiting each units

    Time frame: 5 minutes

  3. Incidence of adverse events

    Including desaturation, laryngospasm, hypotension, bradycardia, hemodynamic agent administration, emergence agitation, headache, dizziness, somnolence, cough, shivering, postoperative nausea \& vomiting

    Time frame: 6 hours

  4. Postoperative pain score

    11-point NRS (0-10); for the worst pain

    Time frame: 6 hours

  5. modified Observer's Alertness/Sedation Scale (MOAA/S) at PACU arrival

    Evaluated on a scale of 0 to 5

    Time frame: 30 minutes

  6. modified Aldrete score at PACU arrival

    Evaluated on a scale of 0 to 10

    Time frame: 30 minutes

07

Study locations

1 of 1 sites recruiting
  • ChungAng University Gwangmyeong Hospital
    Gyeonggi-do, Gwangmyeon-si 14353, Korea, Republic of
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Jan 2025, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2024
First posted
Jul 18, 2024
StartActual
Jan 22, 2024
Primary completionEst.
Jan 22, 2025
CompletionEst.
Mar 22, 2025
Last update
Jul 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06507202
Lead sponsor
Chung-Ang University Gwangmyeong Hospital
Responsible party
Se-Hee Min (Assistant professor, Chung-Ang University Gwangmyeong Hospital) — Principal investigator
First posted
Jul 18, 2024
Start date
Jan 22, 2024
Primary completion
Jan 22, 2025 (estimated)
Completion
Mar 22, 2025 (estimated)
Last update
Jul 18, 2024

Study contacts

Se-Hee Min
Contact
seiheemin@gmail.com
+820222221534
Se-Hee Min
study chair · Chung-Ang University Gwangmyeong Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remimazolam

Start the discussion